Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-11-07Clinical Trial Update: A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM) [Phase 3]
Phase III trial evaluating BL-8040 (motixafortide) with G-CSF versus placebo with G-CSF for mobilizing hematopoietic stem cells in autologou…
-
CLINICAL_TRIALS trial_result · 2023-11-03Clinical Trial Update: Lapelga vs Gastrofil [Phase 3]
Phase 3 trial update for Lapelga versus Gastrofil in patients with Multiple Myeloma and Lymphoma; current status is unknown.
-
FDA approval · 2023-11-01FDA Approved: SARCLISA — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for Sarclisa (isatuximab) from Sanofi to expand its label for use in multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2023-10-31Clinical Trial Update: Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients [Phase 1, Phase 2]
Phase 1/2 trial evaluating ixazomib as a replacement for carfilzomib and bortezomib in multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2023-10-27Clinical Trial Update: Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma [Phase 2]
Phase 2 clinical trial update on Auto-Allo Tandem Stem Cell Transplantation for multiple myeloma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-10-26Clinical Trial Update: KRDI in Transplant-Eligible MM [Phase 2]
A Phase 2 study of KRDI in transplant-eligible multiple myeloma has posted results and the trial remains active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2023-10-25Clinical Trial Update: MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb [Phase 2]
This is a Phase 2 study of elranatamab (PF-06863135) as a monotherapy in adults with multiple myeloma who are refractory to a proteasome inh…
-
CLINICAL_TRIALS trial_result · 2023-10-25Clinical Trial Update: Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients [Phase 2]
Phase 2 trial investigating selinexor with clarithromycin, pomalidomide, and dexamethasone for relapsed refractory multiple myeloma; study t…
-
CLINICAL_TRIALS trial_result · 2023-10-25Clinical Trial Update: APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating APG-2575 in combination regimens for relapsed or refractory multiple myeloma and amyloidosis.
-
CLINICAL_TRIALS trial_result · 2023-10-24Clinical Trial Update: Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating Blmf, Lenalidomide, and Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma patients…
-
CLINICAL_TRIALS trial_result · 2023-10-19Clinical Trial Update: Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients [Phase 2]
Phase 2 trial evaluating nonmyeloablative allogeneic stem cell transplantation followed by bortezomib in high-risk multiple myeloma patients…
-
EMA approval · 2023-10-13New treatment option for heavily pre-treated multiple myeloma patients
The EMA announces a new treatment option for heavily pre-treated multiple myeloma patients, expanding options for this difficult-to-treat gr…
-
CLINICAL_TRIALS trial_result · 2023-10-10Clinical Trial Update: Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating leflunomide in patients with relapsed or refractory multiple myeloma has completed with results posted…
-
CLINICAL_TRIALS trial_result · 2023-10-06Clinical Trial Update: Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) [Phase 3]
Phase 3 trial comparing single-agent belantamab mafodotin to pomalidomide plus low-dose dexamethasone in relapsed/refractory multiple myelom…
-
CLINICAL_TRIALS trial_result · 2023-10-06Clinical Trial Update: Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial of bendamustine with bortezomib and pegylated liposomal doxorubicin in multiple myeloma was terminated.
-
FDA approval · 2023-10-05FDA Approved: LENALIDOMIDE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for lenalidomide submitted by Zydus Pharmaceuticals USA Inc. under ANDA210154, updating the lena…
-
CLINICAL_TRIALS trial_result · 2023-09-28Clinical Trial Update: Methods of T Cell Depletion Trial (MoTD) [Phase 2]
Phase 2 trial update for methods of T cell depletion in various hematologic malignancies is ongoing.
-
CLINICAL_TRIALS trial_result · 2023-09-28Clinical Trial Update: Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma [Phase 2]
Phase 2 trial evaluating reduced-intensity conditioning donor stem cell transplantation for relapsed multiple myeloma has been terminated; r…
-
CLINICAL_TRIALS trial_result · 2023-09-26Clinical Trial Update: Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines [Phase 2]
Phase 2 trial evaluating carfilzomib plus elotuzumab and dexamethasone for relapsed multiple myeloma after 1-3 prior treatments has complete…
-
FDA label_change · 2023-09-21FDA Approved: MOZOBIL — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for MOZOBIL (plerixafor) from Sanofi-Aventis U.S. LLC, updating the drug's labeling.
-
CLINICAL_TRIALS trial_result · 2023-09-21Clinical Trial Update: Allo HSCT Using RIC for Hematological Diseases [Phase 2]
Phase 2 trial evaluating allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for various hematologic dise…
-
EMA withdrawal · 2023-09-15EMA recommends non-renewal of authorisation of multiple myeloma medicine Blenrep
EMA recommends non-renewal of the marketing authorisation for Blenrep (belantamab mafodotin) for multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2023-09-11Clinical Trial Update: Stem Cell Translpantation in Multiple Myeloma [Phase 2]
Phase 2 clinical trial update on stem cell transplantation for multiple myeloma.
-
FDA approval · 2023-09-08FDA Approved: APHEXDA — Original Application (Gamida Cell Inc.)
FDA approved APHEXDA (motixafortide) from Gamida Cell as a new drug to mobilize hematopoietic stem cells in adults with multiple myeloma or …
-
CLINICAL_TRIALS trial_result · 2023-09-08Clinical Trial Update: Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients [Phase 2]
Phase 2 clinical trial update evaluating carfilzomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple myeloma patients.